Literature DB >> 15793115

Azithromycin exhibits bactericidal effects on Pseudomonas aeruginosa through interaction with the outer membrane.

Yoshifumi Imamura1, Yasuhito Higashiyama, Kazunori Tomono, Koichi Izumikawa, Katsunori Yanagihara, Hideaki Ohno, Yoshitsugu Miyazaki, Yoichi Hirakata, Yohei Mizuta, Jun-Ichi Kadota, Barbara H Iglewski, Shigeru Kohno.   

Abstract

The aim of the present study was to elucidate the effect of the macrolide antibiotic azithromycin on Pseudomonas aeruginosa. We studied the susceptibility to azithromycin in P. aeruginosa PAO1 using a killing assay. PAO1 cells at the exponential growth phase were resistant to azithromycin. In contrast, PAO1 cells at the stationary growth phase were sensitive to azithromycin. The divalent cations Mg2+ and Ca2+ inhibited this activity, suggesting that the action of azithromycin is mediated by interaction with the outer membranes of the cells, since the divalent cations exist between adjacent lipopolysaccharides (LPSs) and stabilize the outer membrane. The divalent cation chelator EDTA behaved in a manner resembling that of azithromycin; EDTA killed more PAO1 in the stationary growth phase than in the exponential growth phase. A 1-N-phenylnaphthylamine assay showed that azithromycin interacted with the outer membrane of P. aeruginosa PAO1 and increased its permeability while Mg2+ and Ca2+ antagonized this action. Our results indicate that azithromycin directly interacts with the outer membrane of P. aeruginosa PAO1 by displacement of divalent cations from their binding sites on LPS. This action explains, at least in part, the effectiveness of sub-MICs of macrolide antibiotics in pseudomonal chronic airway infection.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15793115      PMCID: PMC1068619          DOI: 10.1128/AAC.49.4.1377-1380.2005

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  20 in total

1.  Effect of calcium and magnesium ions on the susceptibility of Pseudomonas species to tetracycline, gentamicin polymyxin B, and carbenicillin.

Authors:  R F D'amato; C Thornsberry; C N Baker; L A Kirven
Journal:  Antimicrob Agents Chemother       Date:  1975-05       Impact factor: 5.191

2.  Improvement of survival in patients with diffuse panbronchiolitis treated with low-dose erythromycin.

Authors:  S Kudoh; A Azuma; M Yamamoto; T Izumi; M Ando
Journal:  Am J Respir Crit Care Med       Date:  1998-06       Impact factor: 21.405

Review 3.  Cystic fibrosis.

Authors:  R E Wood; T F Boat; C F Doershuk
Journal:  Am Rev Respir Dis       Date:  1976-06

4.  Activity of aminoglycoside antibiotics aganst Pseudomonas aeruginosa: specificity and site of calcium and magnesium antagonism.

Authors:  V M Zimelis; G G Jackson
Journal:  J Infect Dis       Date:  1973-06       Impact factor: 5.226

5.  Sensitivity and resistance to erythromycin in Bacillus subtilis 168: the ribosomal binding of erythromycin and chloramphenicol.

Authors:  S B Taubman; N R Jones; F E Young; J W Corcoran
Journal:  Biochim Biophys Acta       Date:  1966-08-17

6.  Physical, chemical, and immunological properties of lipopolysaccharide released from Escherichia coli by ethylenediaminetetraacetate.

Authors:  L Leive; V K Shovlin; S E Mergenhagen
Journal:  J Biol Chem       Date:  1968-12-25       Impact factor: 5.157

7.  Effect of salt concentration on the apparent in-vitro susceptibility of Pseudomonas and other gram-negative bacilli to gentamicin.

Authors:  A A Medeiros; T F O'Brien; W E Wacker; N F Yulug
Journal:  J Infect Dis       Date:  1971-12       Impact factor: 5.226

8.  Quorum-sensing signals indicate that cystic fibrosis lungs are infected with bacterial biofilms.

Authors:  P K Singh; A L Schaefer; M R Parsek; T O Moninger; M J Welsh; E P Greenberg
Journal:  Nature       Date:  2000-10-12       Impact factor: 49.962

9.  Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial.

Authors:  Lisa Saiman; Bruce C Marshall; Nicole Mayer-Hamblett; Jane L Burns; Alexandra L Quittner; Debra A Cibene; Sarah Coquillette; Ann Yunker Fieberg; Frank J Accurso; Preston W Campbell
Journal:  JAMA       Date:  2003-10-01       Impact factor: 56.272

Review 10.  Macrolide antibiotics for cystic fibrosis.

Authors:  K W Southern; P M Barker; A Solis
Journal:  Cochrane Database Syst Rev       Date:  2003
View more
  38 in total

Review 1.  Applying insights from biofilm biology to drug development - can a new approach be developed?

Authors:  Thomas Bjarnsholt; Oana Ciofu; Søren Molin; Michael Givskov; Niels Høiby
Journal:  Nat Rev Drug Discov       Date:  2013-10       Impact factor: 84.694

2.  Understanding the Impacts of Surface Compositions on the In-Vitro Dissolution and Aerosolization of Co-Spray-Dried Composite Powder Formulations for Inhalation.

Authors:  Sharad Mangal; Rongkun Xu; Heejun Park; Dmitry Zemlyanov; Nivedita Shetty; Yu-Wei Lin; David Morton; Hak-Kim Chan; Jian Li; Qi Tony Zhou
Journal:  Pharm Res       Date:  2018-11-07       Impact factor: 4.200

3.  Using Small-Molecule Adjuvants to Repurpose Azithromycin for Use against Pseudomonas aeruginosa.

Authors:  Veronica B Hubble; Brittany A Hubbard; Bradley M Minrovic; Roberta J Melander; Christian Melander
Journal:  ACS Infect Dis       Date:  2018-11-29       Impact factor: 5.084

Review 4.  Antibacterial and immunomodulatory properties of azithromycin treatment implications for periodontitis.

Authors:  P M Bartold; A H du Bois; S Gannon; D R Haynes; R S Hirsch
Journal:  Inflammopharmacology       Date:  2013-02-28       Impact factor: 4.473

5.  PA5470 Counteracts Antimicrobial Effect of Azithromycin by Releasing Stalled Ribosome in Pseudomonas aeruginosa.

Authors:  Jing Shi; Yiwei Liu; Yueying Zhang; Yongxin Jin; Fang Bai; Zhihui Cheng; Shouguang Jin; Weihui Wu
Journal:  Antimicrob Agents Chemother       Date:  2018-01-25       Impact factor: 5.191

Review 6.  Azithromycin use in patients with cystic fibrosis.

Authors:  N Principi; F Blasi; S Esposito
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-02-17       Impact factor: 3.267

7.  Ribosome protection prevents azithromycin-mediated quorum-sensing modulation and stationary-phase killing of Pseudomonas aeruginosa.

Authors:  Thilo Köhler; Jean-Luc Dumas; Christian Van Delden
Journal:  Antimicrob Agents Chemother       Date:  2007-09-17       Impact factor: 5.191

8.  Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.

Authors:  Xavier Mulet; María D Maciá; Ana Mena; Carlos Juan; José L Pérez; Antonio Oliver
Journal:  Antimicrob Agents Chemother       Date:  2009-02-02       Impact factor: 5.191

9.  Effects of azithromycin in Pseudomonas aeruginosa burn wound infection.

Authors:  David P Nichols; Silvia Caceres; Lindsay Caverly; Cori Fratelli; Sun Ho Kim; Ken Malcolm; Katie R Poch; Milene Saavedra; George Solomon; Jennifer Taylor-Cousar; Samuel Moskowitz; Jerry A Nick
Journal:  J Surg Res       Date:  2013-02-24       Impact factor: 2.192

Review 10.  Role of macrolide therapy in chronic obstructive pulmonary disease.

Authors:  Fernando J Martinez; Jeffrey L Curtis; Richard Albert
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2008
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.